{"filing":{"accession_number":"0001193125-26-341230","cik":"0002036042","ticker":"SION","company_name":"Sionna Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d135438d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2036042/000119312526341230/d135438d8k.htm"},"events":[{"id":26351,"run_id":23942,"accession_number":"0001193125-26-341230","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Sionna announced topline data from two clinical trials: the Phase 2a PreciSION CF trial of SION-719 failed to meet its key efficacy endpoint (sweat chloride reduction), and the company is discontinuing SION-719 as an add-on therapy. The Phase 1 trial of SION-451 dual combinations achieved safety objectives. The company is preserving capital while evaluating next steps for its SION-451 program. This is a material clinical development milestone and strategic pivot that affects the company's pipeline and capital allocation strategy, but does not fit neatly into specific categories like earnings_release, material_impairment, or workforce_reduction—it is a clinical trial failure with operational/strategic consequences.","company_name":"Sionna Therapeutics, Inc.","ticker":"SION","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27442,"accession_number":"0001193125-26-341230","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Sionna announced topline data from two clinical trials: the Phase 2a PreciSION CF trial of SION-719 failed to meet its key efficacy endpoint (sweat chloride reduction), and the company is discontinuing SION-719 as an add-on therapy. The Phase 1 trial of SION-451 dual combinations achieved safety objectives. The company is preserving capital while evaluating next steps for its SION-451 program. This is a material clinical development milestone and strategic pivot that affects the company's pipeline and capital allocation strategy, but does not fit neatly into specific categories like earnings_release, material_impairment, or workforce_reduction—it is a clinical trial failure with operational/strategic consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:16:51.457259+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27442,"accession_number":"0001193125-26-341230","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Sionna announced topline data from two clinical trials: the Phase 2a PreciSION CF trial of SION-719 failed to meet its key efficacy endpoint (sweat chloride reduction), and the company is discontinuing SION-719 as an add-on therapy. The Phase 1 trial of SION-451 dual combinations achieved safety objectives. The company is preserving capital while evaluating next steps for its SION-451 program. This is a material clinical development milestone and strategic pivot that affects the company's pipeline and capital allocation strategy, but does not fit neatly into specific categories like earnings_release, material_impairment, or workforce_reduction—it is a clinical trial failure with operational/strategic consequences.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:16:51.457259+00:00","company_name":"Sionna Therapeutics, Inc.","ticker":"SION","filing_date":"2026-08-10"}]}